The world's first vaccine against dengue, developed by French drugmaker Sanofi, has shown the ability to protect against disease caused by three of four dengue virus strains in a keenly awaited clinical trial in Thailand.
Sanofi said on Wednesday the proof of efficacy was "a key milestone" in the 70-year quest to develop a viable dengue shot, adding the results also confirmed the safety profile of the vaccine candidate.
The mosquito-borne disease - also known as "breakbone fever" - is a threat to nearly 3 billion people and is caused by four different types of virus, none of which confers immunity from the others.
Sanofi's vaccine generated an antibody response for all four dengue virus types, but evidence of protection was only demonstrated against three of the four circulating in Thailand. Sanofi said researchers were carrying out analyses to understand the lack of protection for the fourth serotype.
The company's vaccine unit, Sanofi Pasteur, has already invested 350 million euros ($423 million) in a new French factory to make the three-dose vaccine and believes its product could generate 1 billion euros in yearly sales.
But uptake of the vaccine will depend on precisely how well doctors believe it can protect populations at risk in fast-expanding tropical cities from Rio to Manila, as well as travelers.
Sanofi gave no details on the level of protection in a brief statement. The full data are now being reviewed by scientific experts and public health officials, with detailed results to be published later this year.
Sanofi previously said it planned to present the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.
Large-scale late-stage Phase III clinical studies with 31,000 participants are under way with Sanofi's vaccine in 10 countries in Asia and Latin America.
There are 883 confirmed cases of the deadly virus, out of which 319 people have died since 2012, the WHO says
WHO announces one million doses of Ebola vaccine to be produced in 2015
That pact would aim to improve on two decades of stuttering cooperation and rein in emissions of carbon dioxide blamed for a disruptive rise in temperatures
The World Health Organization last month urged the use of blood-derived products and serum from survivors.
Pentagon rapid-response Ebola medical team was scheduled to begin training at Fort Sam Houston in San Antonio, Texas
Extensively drug-resistant TB (XDR-TB), which is even more expensive and difficult to treat than multi drug-resistant (MDR-TB) strains, has now been reported in 100 countries around the world.
Device can be used in the field without special equipment, according to developers
The technique involved transplanting what are known as olfactory ensheathing cells into the patient's spinal cord and constructing a "nerve bridge" between two stumps of the damaged spinal column.
The meeting in Cuba is aimed at keeping Ebola at bay and it brings together senior officials from the ALBA bloc of nations
Wildlife conservationists have struggled to reverse a decline in numbers of several African species, undermined by ferocious poaching by gangs which mostly ship the ivory to Asia.
Jerald Dennis is feeling stigmatized by his neighbors and has been shunned by his friends
Peru's 2,679 glaciers, spread over 19 snow-capped mountain ranges, are the source of the vast majority of the country's drinking water.
Some 85 percent of people said they thought the disease spread through sneezing or coughing, despite the fact that the World Health Organization regards that type of transmission as unlikely
No approved specific drug or treatment available for battling fatal pandemic virus hitting many West African countries
The death toll so far in the outbreak, first reported in Guinea in March, has reached 4,447 from a total of 8,914 cases, said WHO Assistant Director General Bruce Aylward.
The world's fifth-largest user of nuclear power has around 70 percent, or nearly 9,000 tonnes, of its used fuel stacked in temporary storage pools